OFIX

SEC source: 0001209191-19-037407 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,053

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019.

F2 · shares: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.31 to $51.31, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-19-036920 · doc4.xml · nonDerivative · entry 1

SICARD JOHN · CIK 0001734027 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,331

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 11, 2019.

SEC source: 0001209191-19-036916 · doc4.xml · nonDerivative · entry 1

Paolucci Michael E · CIK 0001599463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,860

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 11, 2019.

SEC source: 0001209191-19-036918 · doc4.xml · nonDerivative · entry 1

Sainz Maria · CIK 0001437768 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,833

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 11, 2019.

SEC source: 0001209191-19-036914 · doc4.xml · nonDerivative · entry 1

MATRICARIA RONALD A · CIK 0001221872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,100

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 11, 2019.

SEC source: 0001209191-19-036910 · doc4.xml · nonDerivative · entry 1

MARKS LILLY · CIK 0001645735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,696

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 11, 2019.

SEC source: 0001209191-19-036908 · doc4.xml · nonDerivative · entry 1

Lukianov Alexis V · CIK 0001289410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,733

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 11, 2019.

SEC source: 0001209191-19-036903 · doc4.xml · nonDerivative · entry 1

Hinrichs James F. · CIK 0001506974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,998

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 11, 2019.

SEC source: 0001209191-19-030364 · doc4.xml · nonDerivative · entry 2

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,820

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019.

F3 · shares: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.24 to $54.59, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001209191-19-030364 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,120

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019.

F2 · shares: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.21 to $54.16, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-19-026214 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,417

SEC source: 0001209191-19-025331 · doc4.xml · nonDerivative · entry 2

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,488

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019.

F3 · shares: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.38 to $53.36, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001209191-19-025331 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,237

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019.

F2 · shares: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.37 to $52.36, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-19-024379 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,909

SEC source: 0001209191-19-024376 · doc4.xml · nonDerivative · entry 1

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,202

SEC source: 0001209191-19-024370 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,760

SEC source: 0001209191-19-024365 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,375

SEC source: 0001209191-19-023388 · doc4.xml · derivative · entry 4

Bianchi Davide · CIK 0001587881 · President, Global Extremities

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,228

Underlying: Common Stock · 6,228 shares

Expires 2022-04-01

F4 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2019 to April 1, 2022. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 1, 2019, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-19-023388 · doc4.xml · derivative · entry 3

Bianchi Davide · CIK 0001587881 · President, Global Extremities

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,318

Underlying: Common Stock · 10,318 shares

Expires 2029-04-01

F3 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2019.

SEC source: 0001209191-19-023388 · doc4.xml · nonDerivative · entry 2

Bianchi Davide · CIK 0001587881 · President, Global Extremities

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,196

F2 · shares: Represents time-based vesting restricted stock units that vest on the second anniversary of the grant date, April 1, 2019.

SEC source: 0001209191-19-023388 · doc4.xml · nonDerivative · entry 1

Bianchi Davide · CIK 0001587881 · President, Global Extremities

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,830

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2019.

SEC source: 0001209191-19-023382 · doc4.xml · derivative · entry 4

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,206

Underlying: Common Stock · 7,206 shares

Expires 2022-04-01

F4 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2019 to April 1, 2022. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 1, 2019, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-19-023382 · doc4.xml · derivative · entry 3

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,939

Underlying: Common Stock · 11,939 shares

Expires 2029-04-01

F3 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2019.

SEC source: 0001209191-19-023382 · doc4.xml · nonDerivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,157

F2 · shares: Represents time-based vesting restricted stock units that vest on the second anniversary of the grant date, April 1, 2019.

SEC source: 0001209191-19-023382 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,755

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2019.

SEC source: 0001209191-19-023375 · doc4.xml · derivative · entry 4

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,673

Underlying: Common Stock · 6,673 shares

Expires 2022-04-01

F4 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2019 to April 1, 2022. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 1, 2019, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-19-023375 · doc4.xml · derivative · entry 3

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,055

Underlying: Common Stock · 11,055 shares

Expires 2029-04-01

F3 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2019.

SEC source: 0001209191-19-023375 · doc4.xml · nonDerivative · entry 2

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,521

F2 · shares: Represents time-based vesting restricted stock units that vest on the second anniversary of the grant date, April 1, 2019.

SEC source: 0001209191-19-023375 · doc4.xml · nonDerivative · entry 1

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,972

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2019.

SEC source: 0001209191-19-023373 · doc4.xml · derivative · entry 4

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,206

Underlying: Common Stock · 7,206 shares

Expires 2022-04-01

F4 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2019 to April 1, 2022. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 1, 2019, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-19-023373 · doc4.xml · derivative · entry 3

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,939

Underlying: Common Stock · 11,939 shares

Expires 2029-04-01

F3 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2019.

SEC source: 0001209191-19-023373 · doc4.xml · nonDerivative · entry 2

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,095

F2 · shares: Represents time-based vesting restricted stock units that vest on the second anniversary of the grant date, April 1, 2019.

SEC source: 0001209191-19-023373 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,508

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2019.

SEC source: 0001209191-19-023371 · doc4.xml · derivative · entry 4

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,829

Underlying: Common Stock · 7,829 shares

Expires 2022-04-01

F4 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2019 to April 1, 2022. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 1, 2019, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-19-023371 · doc4.xml · derivative · entry 3

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,971

Underlying: Common Stock · 12,971 shares

Expires 2029-04-01

F3 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2019.

SEC source: 0001209191-19-023371 · doc4.xml · nonDerivative · entry 2

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,738

F2 · shares: Represents time-based vesting restricted stock units that vest on the second anniversary of the grant date, April 1, 2019.

SEC source: 0001209191-19-023371 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,040

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2019.

SEC source: 0001209191-19-023365 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,437

F1 · shares: Represents time-based vesting restricted stock units that vest on the first anniversary of the grant date, April 1, 2019.

SEC source: 0001209191-19-019149 · doc4.xml · nonDerivative · entry 1

Bianchi Davide · CIK 0001587881 · President, Global Extremities

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,716

SEC source: 0001209191-19-019145 · doc4.xml · nonDerivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,152

SEC source: 0001209191-19-019145 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,061

SEC source: 0001209191-19-019147 · doc4.xml · nonDerivative · entry 2

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,636

SEC source: 0001209191-19-019147 · doc4.xml · nonDerivative · entry 1

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,256

SEC source: 0001209191-19-019140 · doc4.xml · nonDerivative · entry 2

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,125

SEC source: 0001209191-19-019140 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,606

SEC source: 0001209191-19-019136 · doc4.xml · nonDerivative · entry 2

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,850

SEC source: 0001209191-19-019136 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,991

SEC source: 0001209191-19-011640 · doc4.xml · nonDerivative · entry 2

Bianchi Davide · CIK 0001587881 · President, Global Extremities

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,666

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.

SEC source: 0001209191-19-011640 · doc4.xml · nonDerivative · entry 1

Bianchi Davide · CIK 0001587881 · President, Global Extremities

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,865

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.

SEC source: 0001209191-19-003953 · doc4.xml · nonDerivative · entry 2

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,401

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2018.